Due to RCC being highly vascular and PD‐L1 being highly expressed in cancer cells, numerous studies propose combining PD‐1 inhibitors with VEGF/VEGFR inhibitors (TKI) as a feasible therapy to prevent RCC recurrence [10, 11, 12]. Here, KDR is linked to renal cell carcinoma.